Resources Product Information > Product Information Package Inserts Case Studies Publications Implementation & Billing > Implementation Tools Coding & Billing Webinars & Podcasts Free CE Modules Standards & Policies > FDA Federal Register AABB Standards and TA-GVHD Prevention FDA Guidance on Babesia FDA Final Guidance All Topics Case Studies Coding & Billing Implementation Tools Package Inserts Product Information OneBlood – “Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs LVDS Screened Platelets” – INTERCEPT Blood System Download View Cerus Corporation – “Impact of Pathogen Reduction (PR) vs. LVDS Testing on Platelet Availability: A Study Based on Real-World Experience” – INTERCEPT Blood System Download View Case Study: Assessing Platelet Availability – PR vs. LVDS Download View Puerto Rico Blood Center Case Study – INTERCEPT Blood System Download View US Tertiary Care Hospital Case Study – INTERCEPT Blood System Download View UCSD – “Phased Implementation of Pathogen-Reduced Platelets in a Health System”- INTERCEPT Blood System Download View Yale-New Haven Hospital – “Logistical Management of Incorporating Pathogen Reduced Platelets into Inventory”-INTERCEPT Blood System Download View Roswell Park Cancer Insitute – “The Effects of PAS and PR on Platelet Use”-INTERCEPT Blood System Download View Case Study: Hospital Demand, FDA Guidance Drives Pathogen Reduction Scale-Up Download View Case Study: Stanford Blood Center – Implementing Pathogen Reduction for 100% of Platelet Components Download View